Civitas Therapeutics
Curated by SignalPulmonary delivery therapies for relief from intermittent debilitating motor fluctuations
Overview
Civitas Therapeutics is a biopharmaceutical company focused on developing a robust pipeline of inhaled therapeutics with the clinically-proven ARCUS dry powder pulmonary delivery platform. Their lead program, CVT-301, is being developed as adjunctive PRN therapy to provide Parkinson’s disease patients with rapid and reliable relief from intermittent debilitating motor fluctuations (OFF episodes). CVT-301 is a system comprised of a dry powder L-dopa formulation that is contained within blister-packed capsules and administered via a proprietary, pocket-size, reusable inhaler. CVT-301 can provide rapid delivery of L-dopa in conjunction with a patient’s optimized oral L-dopa regimen.
Key facts
- Founded
- 2009
- Headquarters
- Chelsea, United States
- Stage
- Sign up to view
- Industry
- Life Sciences Technology
Contact
- Primary office
- Sign up to view